Clinical Trial Update: A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for JBI-802, an LSD1/HDAC6 inhibitor, in locally advanced or metastatic solid tumors. No current status available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• JBI-802

Snippet

Sponsor: Jubilant Therapeutics Inc. | Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN